| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6913768 | TAKEDA PHARMS USA | Sustained release delivery of amphetamine salts |
May, 2023
(11 months ago) | |
| US9173857 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
May, 2026
(2 years from now) | |
| US8846100 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
Aug, 2029
(5 years from now) | |
Mydayis is owned by Takeda Pharms Usa.
Mydayis contains Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate.
Mydayis has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Mydayis are:
- USRE41148
- USRE42096
- US6913768
Mydayis was authorised for market use on 20 June, 2017.
Mydayis is available in capsule, extended release;oral dosage forms.
Mydayis can be used as treatment of attention deficit hyperactivity disorder.
The generics of Mydayis are possible to be released after 24 August, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 20, 2020 |
| Pediatric Exclusivity(PED) | Mar 13, 2023 |
| M(M-248) | Sep 13, 2022 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
MYDAYIS family patents
